Bushveld Minerals Limited

Bushveld Minerals welcomes AfriTin’s new loan facility

Bushveld will still provide surety over the new £2mln loan, but it said this was “less onerous” as it is not a cash collateralised guarantee

Bushveld Minerals Limited
Bushveld spun off its tin business back in 2017

Vanadium producer Bushveld Minerals Limited (LON:BMN) has outlined how AfriTin Mining Limited’s (LON:ATM) new loan facility affects it.

Bushveld owns an 8% stake in AfriTin, which this morning announced it has agreed a new £2mln (35mln Rand) working capital facility with Nedbank Namibia.

READ: AfriTin sets up new loan facility as production nears

Back in May, Bushveld agreed to provide AfriTin with a short-term working capital facility also for 30mln Rand while the latter finalised its longer-term debt financing.

Bushveld will provide surety over the Nedbank loan, meaning it would assume responsibility for the debt obligation in the unlikely event of default.

“The above is less onerous on Bushveld Minerals as it is not a cash collateralised guarantee,” the company said in a statement.

Bushveld added: “The company is comfortable with the progress that AfriTin has made towards production at its Namibian flagship project and with the security it retains from AfriTin for the suretyship in the form of a notarial bond over the AfriTin processing plant.”

Bushveld shares were up almost 6% to 21.4p on Friday afternoon.

Quick facts: Bushveld Minerals Limited

Price: £0.23

Market: LSE
Market Cap: £254.59 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Bushveld Minerals Limited named herein, including the promotion by the Company of Bushveld Minerals Limited in any Content on the Site, the...



Investor Update: hVIVO’s mosquito vaccine moves into the clinic

Headlines from the Proactive Investors UK newsroom.  Clinical services group hVIVO’s (LON:HVO) experimental vaccine AGS-v PLUS is to undergo a phase 1 safety trial at the University of Maryland school of medicine. The vaccine is designed to protect against mosquito-borne diseases such as...

on 07/31/2019

2 min read